Barbara Schadler - Roche Holding Head Communications
| RHO6 Stock | EUR 33.63 0.59 1.72% |
Insider
Barbara Schadler is Head Communications of Roche Holding Ltd
| Age | 61 |
| Phone | 41 61 688 11 11 |
| Web | https://www.roche.com |
Roche Holding Management Efficiency
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Robert Bradway | Amgen Inc | 60 | |
| Gabriel Harnier | Bayer Aktiengesellschaft | 52 | |
| Katsuyoshi Sugita | Astellas Pharma | N/A | |
| David MD | Amgen Inc | 60 | |
| Esteban Santos | Amgen Inc | 55 | |
| Jennifer Mauer | Merck Co | N/A | |
| Lisa LeCointeCephas | Merck Co | 41 | |
| Kenneth Frazier | Merck Co | 67 | |
| Caroline Litchfield | Merck Co | 54 | |
| Murdo Gordon | Amgen Inc | 56 | |
| Werner Baumann | Bayer Aktiengesellschaft | 61 | |
| Richard DeLuca | Merck Co | 60 | |
| Minoru Kikuoka | Astellas Pharma | N/A | |
| Jennifer Zachary | Merck Co | 45 | |
| Michael Preuss | Bayer Aktiengesellschaft | N/A | |
| Naoki BSc | Astellas Pharma | N/A | |
| Nobue Yasuda | Astellas Pharma | N/A | |
| Chihiro Yokota | Astellas Pharma | N/A | |
| Heiko Schipper | Bayer Aktiengesellschaft | 54 | |
| BerndPeter Bier | Bayer Aktiengesellschaft | 56 | |
| Peter Griffith | Amgen Inc | 64 | |
Management Performance
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 |
Roche Holding Leadership Team
Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Claudia Bockstiegel, G Counsel | ||
| Barbara Schadler, Head Communications | ||
| Johannes MD, Head Devel | ||
| Bruno Eschli, Head Relations | ||
| Thomas Schinecker, Chief Diagnostics | ||
| Cristina Wilbur, Chief Officer | ||
| William Anderson, Chief Pharmaceuticals | ||
| Alan Hippe, Chief Officer | ||
| Severin Schwan, CEO Director | ||
| Pascale Schmidt, Chief Officer |
Roche Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 273.87 B | |||
| Shares Outstanding | 6.39 B | |||
| Shares Owned By Institutions | 1.28 % | |||
| Price To Earning | 21.74 X | |||
| Price To Book | 9.68 X | |||
| Price To Sales | 3.82 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Roche Stock
Roche Holding financial ratios help investors to determine whether Roche Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Roche with respect to the benefits of owning Roche Holding security.